N-methyl-D-aspartate receptor encephalitis: laboratory diagnostics and comparative clinical features in adults and children

References

• Graus F, Titulaer M, Balu R, et al. A clinical approach to diagnosis of autoimmune encephalitis. Lancet Neurol. 2016;15:391–404.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Tuzun E, Wu HY, et al. Paraneoplastic anti-N-methyl-D-aspartate receptor encephalitis associated with ovarian teratoma. Ann Neurol. 2007;61:25–36.
   PubMed Web of Science ®Google Scholar
• Irani SR, Bera K, Waters P, et al. N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. Brain. 2010;133:1655–1667.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study. Lancet Neurol. 2013;12:157–165.
   PubMed Web of Science ®Google Scholar
• Hutchinson M, Waters P, McHugh J, et al. Progressive encephalomyelitis, rigidity, and myoclonus: a novel glycine receptor antibody. Neurology. 2008;71:1291–1292.
   PubMed Web of Science ®Google Scholar
• Lai M, Hughes EG, Peng X, et al. AMPA receptor antibodies in limbic encephalitis alter synaptic receptor location. Ann Neurol. 2009;65:424–434.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Lai M, Peng X, et al. Antibodies to the GABAB receptor in limbic encephalitis with seizures: case series and characterisation of the antigen. Lancet Neurol. 2010;9:67–69.
   PubMed Web of Science ®Google Scholar
• Lai M, Huijbers M, Lancaster E, et al. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lancet Neurol. 2010;9:776–785.
   PubMed Web of Science ®Google Scholar
• Irani SR, Alexander S, Waters P, et al. Antibodies to Kv1 potassium channel-complex proteins leucine-rich, glioma inactivated 1 protein and contactin-associated protein-2 in limbic encephalitis, Morvan’s syndrome and acquired neuromyotonia. Brain. 2010;133:2734–2748.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Martinez-Hernandez E, Titulaer M, et al. Antibodies to metabotropic glutamate receptor 5 in the Ophelia syndrome. Neurology. 2011;77:1698–1701.
   PubMed Web of Science ®Google Scholar
• Dale RC, Merheb V, Pillai S, et al. Antibodies to surface dopamine-2 receptor in autoimmune movement and psychiatric disorders. Brain. 2012;135:3453–3468.
   PubMed Web of Science ®Google Scholar
• Boronat A, Gelfand JM, Gresa-Arribas N, et al. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Ann Neurol. 2013;73:120–128.
   PubMed Web of Science ®Google Scholar
• Petit-Pedrol M, Armangue T, Peng X, et al. Encephalitis with refractory seizures, status epilepticus, and antibodies to the GABAA receptor: a case series, characterisation of the antigen, and analysis of the effects of antibodies. Lancet Neurol. 2014;13:276–286.
   PubMed Web of Science ®Google Scholar
• Sabater L, Gaig C, Gelpi E, et al. A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study. Lancet Neurol. 2014;13:575–586.
   PubMed Web of Science ®Google Scholar
• Gresa-Arribas N, Planaguma J, Petit-Pedrol M, et al. Human neurexin-3alpha antibodies associate with encephalitis and alter synapse development. Neurology. 2016;86:2235–2242.
   PubMed Web of Science ®Google Scholar
• Granerod J, Ambrose HE, Davies NW, et al. Causes of encephalitis and differences in their clinical presentations in England: a multicentre, population-based prospective study. Lancet Infect Dis. 2010;10:835–844.
   PubMed Web of Science ®Google Scholar
• Armangue T, Leypoldt F, Dalmau J. Autoimmune encephalitis as differential diagnosis of infectious encephalitis. Curr Opin Neurol. 2014;27:361–368.
   PubMed Web of Science ®Google Scholar
• Zhang L, Wu MQ, Hao ZL, et al. Clinical characteristics, treatments, and outcomes of patients with anti-N-methyl-d-aspartate receptor encephalitis: a systematic review of reported cases. Epilepsy Behav. 2017;68:57–65.
   PubMed Web of Science ®Google Scholar
• Gable MS, Sheriff H, Dalmau J, et al. The frequency of autoimmune N-methyl-D-aspartate receptor encephalitis surpasses that of individual viral etiologies in young individuals enrolled in the California Encephalitis Project. Clin Infect Dis. 2012;54:899–904.
   PubMed Web of Science ®Google Scholar
• Diamond B, Honig G, Mader S, et al. Brain-reactive antibodies and disease. Annu Rev Immunol. 2013;31:345–385.
   PubMed Web of Science ®Google Scholar
• Dahm L, Ott C, Steiner J, et al. Seroprevalence of autoantibodies against brain antigens in health and disease. Ann Neurol. 2014;76:82–94.
   PubMed Web of Science ®Google Scholar
• Titulaer MJ, McCracken L, Gabilondo I, et al. Late-onset anti-NMDA receptor encephalitis. Neurology. 2013;81:1058–1063.
   PubMed Web of Science ®Google Scholar
• Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162:850–856.e852.
   PubMed Web of Science ®Google Scholar
• Darnell RB. Onconeural antigens and the paraneoplastic neurologic disorders: at the intersection of cancer, immunity, and the brain. Proc Natl Acad Sci U S A. 1996;93:4529–4536.
   PubMed Web of Science ®Google Scholar
• Armangue T, Leypoldt F, Malaga I, et al. Herpes simplex virus encephalitis is a trigger of brain autoimmunity. Ann Neurol. 2014;75:317–323.
   PubMed Web of Science ®Google Scholar
• Mohammad SS, Sinclair K, Pillai S, et al. Herpes simplex encephalitis relapse with chorea is associated with autoantibodies to N-Methyl-D-aspartate receptor or dopamine-2 receptor. Mov Disord. 2014;29:117–122.
   PubMed Web of Science ®Google Scholar
• Nosadini M, Mohammad SS, Corazza F, et al. Herpes simplex virus-induced anti-N-methyl-d-aspartate receptor encephalitis: a systematic literature review with analysis of 43 cases. Dev Med Child Neurol. 2017;59:796–805.
   PubMed Web of Science ®Google Scholar
• De Tiege X, Rozenberg F, Des Portes V, et al. Herpes simplex encephalitis relapses in children: differentiation of two neurologic entities. Neurology. 2003;61:241–243.
   PubMed Web of Science ®Google Scholar
• Armangue T, Moris G, Cantarin-Extremera V, et al. Autoimmune post-herpes simplex encephalitis of adults and teenagers. Neurology. 2015;85:1736–1743.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Gleichman AJ, Hughes EG, et al. Anti-NMDA-receptor encephalitis: case series and analysis of the effects of antibodies. Lancet Neurol. 2008;7:1091–1098.
   PubMed Web of Science ®Google Scholar
• Schabitz WR, Rogalewski A, Hagemeister C, et al. VZV brainstem encephalitis triggers NMDA receptor immunoreaction. Neurology. 2014;83:2309–2311.
   PubMed Web of Science ®Google Scholar
• Solis N, Salazar L, Hasbun R. Anti-NMDA Receptor antibody encephalitis with concomitant detection of Varicella zoster virus. J Clin Virol. 2016;83:26–28.
   PubMed Web of Science ®Google Scholar
• Linnoila JJ, Binnicker MJ, Majed M, et al. CSF herpes virus and autoantibody profiles in the evaluation of encephalitis. Neurol Neuroimmunol Neuroinflamm. 2016;3:e245.
   PubMed Web of Science ®Google Scholar
• Venancio P, Brito MJ, Pereira G, et al. Anti-N-methyl-D-aspartate receptor encephalitis with positive serum antithyroid antibodies, IgM antibodies against mycoplasma pneumoniae and human herpesvirus 7 PCR in the CSF. Pediatr Infect Dis J. 2014;33:882–883.
   PubMed Web of Science ®Google Scholar
• Gleichman AJ, Spruce LA, Dalmau J, et al. Anti-NMDA receptor encephalitis antibody binding is dependent on amino acid identity of a small region within the GluN1 amino terminal domain. J Neurosci. 2012;32:11082–11094.
   PubMed Web of Science ®Google Scholar
• Mikasova L, De Rossi P, Bouchet D, et al. Disrupted surface cross-talk between NMDA and Ephrin-B2 receptors in anti-NMDA encephalitis. Brain. 2012;135:1606–1621.
   PubMed Web of Science ®Google Scholar
• Hughes EG, Peng X, Gleichman AJ, et al. Cellular and synaptic mechanisms of anti-NMDA receptor encephalitis. J Neurosci. 2010;30:5866–5875.
   PubMed Web of Science ®Google Scholar
• Planagumà J, Leypoldt F, Mannara F, et al. Human N-methyl D-aspartate receptor antibodies alter memory and behaviour in mice. Brain. 2015;138:94–109.
   PubMed Web of Science ®Google Scholar
• Martinez-Hernandez E, Horvath J, Shiloh-Malawsky Y, et al. Analysis of complement and plasma cells in the brain of patients with anti-NMDAR encephalitis. Neurology. 2011;77:589–593.
   PubMed Web of Science ®Google Scholar
• Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Lancet Neurol. 2014;13:167–177.
   PubMed Web of Science ®Google Scholar
• Kreye J, Wenke NK, Chayka M, et al. Human cerebrospinal fluid monoclonal N-methyl-D-aspartate receptor autoantibodies are sufficient for encephalitis pathogenesis. Brain. 2016;139:2641–2652.
   PubMed Web of Science ®Google Scholar
• Hammer C, Stepniak B, Schneider A, et al. Neuropsychiatric disease relevance of circulating anti-NMDA receptor autoantibodies depends on blood-brain barrier integrity. Mol Psychiatry. 2014;19:1143–1149.
   PubMed Web of Science ®Google Scholar
• Ehrenreich H. Autoantibodies against the N-Methyl-d-Aspartate receptor subunit NR1: untangling apparent inconsistencies for clinical practice. Front Immunol. 2017;8:181.
   PubMed Web of Science ®Google Scholar
• Gastaldi M, Thouin A, Franciotta D, et al. Pitfalls in the detection of N-methyl-d-aspartate-receptor (NMDA-R) antibodies. Clin Biochem. 2017;50:354–355.
   PubMed Web of Science ®Google Scholar
• Lancaster E, Leypoldt F, Titulaer MJ, et al. Immunoglobulin G antibodies to the N-Methyl-D-aspartate receptor are distinct from immunoglobulin A and immunoglobulin M responses. Ann Neurol. 2015;77:183.
   PubMed Web of Science ®Google Scholar
• Jezequel J, Johansson EM, Dupuis JP, et al. Dynamic disorganization of synaptic NMDA receptors triggered by autoantibodies from psychotic patients. Nature Communications. 2017;8:1791.
   PubMed Web of Science ®Google Scholar
• Moghaddam B, Javitt D. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology. 2012;37:4–15.
   PubMed Web of Science ®Google Scholar
• Krystal JH, Karper LP, Seibyl JP, et al. Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch Gen Psychiatry. 1994;51:199–214.
   PubMed Web of Science ®Google Scholar
• Javitt DC, Zukin SR. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry. 1991;148:1301–1308.
   PubMed Web of Science ®Google Scholar
• Masdeu JC, Dalmau J, Berman KF. NMDA receptor internalization by autoantibodies: a reversible mechanism underlying psychosis? Trends Neurosci. 2016 Mar 22;pii:S0166-2236(16)00047-3. [Epub ahead of print]. DOI:10.1016/j.tins.2016.02.006.
   Google Scholar
• Marchant A, Goldman M. T cell-mediated immune responses in human newborns: ready to learn? Clin Exp Immunol. 2005;141:10–18.
   PubMed Web of Science ®Google Scholar
• Cutolo M, Capellino S, Sulli A, et al. Estrogens and autoimmune diseases. Ann N Y Acad Sci. 2006;1089:538–547.
   PubMed Web of Science ®Google Scholar
• Davies TF. Really significant genes for autoimmune thyroid disease do not exist–so how can we predict disease? Thyroid. 2007;17:1027–1029.
   PubMed Web of Science ®Google Scholar
• Eschler DC, Hasham A, Tomer Y. Cutting edge: the etiology of autoimmune thyroid diseases. Clin Rev Allergy Immunol. 2011;41:190–197.
   PubMed Web of Science ®Google Scholar
• Hilderink M, Titulaer MJ, Schreurs MW, et al. Transient anti-NMDAR encephalitis in a newborn infant due to transplacental transmission. Neurol Neuroimmunol Neuroinflamm. 2015;2:e126.
   PubMed Web of Science ®Google Scholar
• Marc T. Brain development and the immune system: an introduction to inflammatory and infectious diseases of the child’s brain. Dev Med Child Neurol. 2013;112:1087–1089.
   Google Scholar
• Zinkernagel RM. Maternal antibodies, childhood infections, and autoimmune diseases. N Engl J Med. 2001;345:1331–1335.
   PubMed Web of Science ®Google Scholar
• Barlow DJ, Edwards MS, Thornton JM. Continuous and discontinuous protein antigenic determinants. Nature. 1986;322:747–748.
   PubMed Web of Science ®Google Scholar
• Sanders J, Jeffreys J, Depraetere H, et al. Thyroid-stimulating monoclonal antibodies. Thyroid. 2002;12:1043–1050.
   PubMed Web of Science ®Google Scholar
• Dalmau J, Lancaster E, Martinez-Hernandez E, et al. Clinical experience and laboratory investigations in patients with anti-NMDAR encephalitis. Lancet Neurol. 2011;10:63–74.
   PubMed Web of Science ®Google Scholar
• McCracken L, Zhang J, Greene M, et al. Improving the antibody-based evaluation of autoimmune encephalitis. Neurol Neuroimmunol Neuroinflamm. 2017;4:e404.
   PubMed Web of Science ®Google Scholar
• Zuliani L, Zoccarato M, Gastaldi M, et al. Diagnostics of autoimmune encephalitis associated with antibodies against neuronal surface antigens. Neurol Sci. 2017;38:225–229.
   PubMed Web of Science ®Google Scholar
• Florance NR, Davis RL, Lam C, et al. Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis in children and adolescents. Ann Neurol. 2009;66:11–18.
   PubMed Web of Science ®Google Scholar
• Ho A, Mohammad S, Pillai S, et al. High sensitivity and specificity in proposed clinical diagnostic criteria for anti-N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2017;59:1256–1260.
   PubMed Web of Science ®Google Scholar
• Puoti G, Bizzi A, Forloni G, et al. Sporadic human prion diseases: molecular insights and diagnosis. Lancet Neurol. 2012;11:618–628.
   PubMed Web of Science ®Google Scholar
• Solomon T, Michael BD, Smith PE, et al. Management of suspected viral encephalitis in adults–Association of British Neurologists and British Infection Association National Guidelines. J Infect. 2012;64:347–373.
   PubMed Web of Science ®Google Scholar
• Tse L, Barr AM, Scarapicchia V, et al. Neuroleptic malignant syndrome: a review from a clinically oriented perspective. Curr Neuropharmacol. 2015;13:395–406.
   PubMed Web of Science ®Google Scholar
• Spatola M, Novy J, Du Pasquier R, et al. Status epilepticus of inflammatory etiology: a cohort study. Neurology. 2015;85:464–470.
   PubMed Web of Science ®Google Scholar
• Kayser MS, Titulaer MJ, Gresa-Arribas N, et al. Frequency and characteristics of isolated psychiatric episodes in anti-N-methyl-d-aspartate receptor encephalitis. JAMA Neurol. 2013;70:1133–1139.
   PubMed Web of Science ®Google Scholar
• Bien CG, Granata T, Antozzi C, et al. Pathogenesis, diagnosis and treatment of Rasmussen encephalitis: a European consensus statement. Brain. 2005;128:454–471.
   PubMed Web of Science ®Google Scholar
• Arnulf I, Rico TJ, Mignot E. Diagnosis, disease course, and management of patients with Kleine-Levin syndrome. Lancet Neurol. 2012;11:918–928.
   PubMed Web of Science ®Google Scholar
• Kurian MA, Gissen P, Smith M, et al. The monoamine neurotransmitter disorders: an expanding range of neurological syndromes. Lancet Neurol. 2011;10:721–733.
   PubMed Web of Science ®Google Scholar
• van Baalen A, Vezzani A, Hausler M, et al. Febrile infection-related epilepsy syndrome: clinical review and hypotheses of epileptogenesis. Neuropediatrics. 2017;48:5–18.
   PubMed Web of Science ®Google Scholar
• Nosadini M, Boniver C, Zuliani L, et al. Longitudinal electroencephalographic (EEG) findings in pediatric anti-N-methyl-D-aspartate (anti-NMDA) receptor encephalitis: the Padua experience. J Child Neurol. 2015;30:238–245.
   PubMed Web of Science ®Google Scholar
• Huang Q, Wu Y, Qin R, et al. Clinical characteristics and outcomes between children and adults with anti-N-Methyl-D-Aspartate receptor encephalitis. J Neurol. 2016;263:2446–2455.
   PubMed Web of Science ®Google Scholar
• Mohammad SS, Fung VS, Grattan-Smith P, et al. Movement disorders in children with anti-NMDAR encephalitis and other autoimmune encephalopathies. Mov Disord. 2014;29:1539–1542.
   PubMed Web of Science ®Google Scholar
• Duan BC, Weng WC, Lin KL, et al. Variations of movement disorders in anti-N-methyl-D-aspartate receptor encephalitis: a nationwide study in Taiwan. Medicine (Baltimore). 2016;95:e4365.
   PubMed Web of Science ®Google Scholar
• Meyfroidt G, Baguley IJ, Menon DK. Paroxysmal sympathetic hyperactivity: the storm after acute brain injury. Lancet Neurol. 2017;16:721–729.
   PubMed Web of Science ®Google Scholar
• Armangue T, Titulaer MJ, Malaga I, et al. Pediatric anti-N-methyl-D-aspartate receptor encephalitis-clinical analysis and novel findings in a series of 20 patients. J Pediatr. 2013;162:850–856.e852.
   PubMed Web of Science ®Google Scholar
• Iizuka T, Yoshii S, Kan S, et al. Reversible brain atrophy in anti-NMDA receptor encephalitis: a long-term observational study. J Neurol. 2010;257:1686–1691.
   PubMed Web of Science ®Google Scholar
• Iizuka T, Kaneko J, Tominaga N, et al. Association of progressive cerebellar atrophy with long-term outcome in patients with anti-N-Methyl-d-Aspartate receptor encephalitis. JAMA Neurol. 2016;73:706–713.
   PubMed Web of Science ®Google Scholar
• Schmitt SE, Pargeon K, Frechette ES, et al. Extreme delta brush: a unique EEG pattern in adults with anti-NMDA receptor encephalitis. Neurology. 2012;79:1094–1100.
   PubMed Web of Science ®Google Scholar
• Gordon-Lipkin E, Yeshokumar AK, Saylor D, et al. Comparative outcomes in children and adults with anti- N-Methyl-D-Aspartate (anti-NMDA) receptor encephalitis. J Child Neurol. 2017 Oct;32(11):930–935. doi:10.1177/088307381772034. Epub 2017 Jul 21.
   Web of Science ®Google Scholar
• Matricardi S, Patrini M, Freri E, et al. Cognitive and neuropsychological evolution in children with anti-NMDAR encephalitis. J Neurol. 2016;263:765–771.
   PubMed Web of Science ®Google Scholar
• Zuliani L, Graus F, Giometto B, et al. Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognition. J Neurol Neurosurg Psychiatry. 2012;83:638–645.
   PubMed Web of Science ®Google Scholar
• Nosadini M, Mohammad SS, Ramanathan S, et al. Immune therapy in autoimmune encephalitis: a systematic review. Expert Rev Neurother. 2015;15:1391–1419.
   PubMed Web of Science ®Google Scholar
• McKeon A. Paraneoplastic and other autoimmune disorders of the central nervous system. Neurohospitalist. 2013;3:53–64.
   PubMedGoogle Scholar
• Lancaster E. The Diagnosis and Treatment of Autoimmune Encephalitis. J Clin Neurol. 2016;12:1–13.
   PubMed Web of Science ®Google Scholar
• Dale RC, Gorman MP, Lim M. Autoimmune encephalitis in children: clinical phenomenology, therapeutics, and emerging challenges. Curr Opin Neurol. 2017;30:334–344.
   PubMed Web of Science ®Google Scholar
• Gastaldi M, Thouin A, Vincent A. Antibody-mediated autoimmune encephalopathies and immunotherapies. Neurotherapeutics. 2016;13:147–162.
   PubMed Web of Science ®Google Scholar
• Kahn I, Helman G, Vanderver A, et al. Anti-N-methyl-d-aspartate (NMDA) receptor encephalitis. J Child Neurol. 2017;32:243–245.
   PubMed Web of Science ®Google Scholar
• Bartolini L, Muscal E. Differences in treatment of anti-NMDA receptor encephalitis: results of a worldwide survey. J Neurol. 2017;264:647–653.
   PubMed Web of Science ®Google Scholar
• Iizuka T, Sakai F, Ide T, et al. Anti-NMDA receptor encephalitis in Japan: long-term outcome without tumor removal. Neurology. 2008;70:504–511.
   PubMed Web of Science ®Google Scholar
• Johnson N, Henry C, Fessler AJ, et al. Anti-NMDA receptor encephalitis causing prolonged nonconvulsive status epilepticus. Neurology. 2010;75:1480–1482.
   PubMed Web of Science ®Google Scholar
• Suppiej A, Nosadini M, Zuliani L, et al. Plasma exchange in pediatric anti-NMDAR encephalitis: a systematic review. Brain Dev. 2016;38:613–622.
   PubMed Web of Science ®Google Scholar
• Cortese A, Franciotta D, Alfonsi E, et al. Combined central and peripheral demyelination: clinical features, diagnostic findings and treatment. J Neur Sci. 2016;363:182–187.
   Google Scholar
• De Silvestro G, Tison T, Vicarioto M, et al. The Italian registry of pediatric therapeutic apheresis: a report on activity during 2005. J Clin Apher. 2009;24:1–5.
   PubMed Web of Science ®Google Scholar
• Kim SH, Huh SY, Lee SJ, et al. A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol. 2013;70:1110–1117.
   PubMed Web of Science ®Google Scholar
• Looney RJ, Huggins J. Use of intravenous immunoglobulin G (IVIG). Best Pract Res Clin Haematol. 2006;19:3–25.
   PubMed Web of Science ®Google Scholar
• Schroder C, Azimzadeh AM, Wu G, et al. Anti-CD20 treatment depletes B-cells in blood and lymphatic tissue of cynomolgus monkeys. Transpl Immunol. 2003;12:19–28.
   PubMed Web of Science ®Google Scholar
• McDonald V, Manns K, Mackie IJ, et al. Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura. J Thromb Haemost. 2010;8:1201–1208.
   PubMed Web of Science ®Google Scholar
• Dale RC, Pillai S, Brilot F. Cerebrospinal fluid CD19(+) B-cell expansion in N-methyl-D-aspartate receptor encephalitis. Dev Med Child Neurol. 2013;55:191–193.
   PubMed Web of Science ®Google Scholar
• Nosadini M, Alper G, Riney CJ, et al. Rituximab monitoring and redosing in pediatric neuromyelitis optica spectrum disorder. Neurol Neuroimmunol Neuroinflammation. 2016;3:e188.
   PubMed Web of Science ®Google Scholar
• Pellkofer HL, Krumbholz M, Berthele A, et al. Long-term follow-up of patients with neuromyelitis optica after repeated therapy with rituximab. Neurology. 2011;76:1310–1315.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee ST, Byun JI, et al. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort. Neurology. 2016;86:1683–1691.
   PubMed Web of Science ®Google Scholar
• Hachiya Y, Uruha A, Kasai-Yoshida E, et al. Rituximab ameliorates anti-N-methyl-D-aspartate receptor encephalitis by removal of short-lived plasmablasts. J Neuroimmunol. 2013;265:128–130.
   PubMed Web of Science ®Google Scholar
• Dale RC, Brilot F, Duffy LV, et al. Utility and safety of rituximab in pediatric autoimmune and inflammatory CNS disease. Neurology. 2014;83:142–150.
   PubMed Web of Science ®Google Scholar
• Demeestere I, Brice P, Peccatori FA, et al. No evidence for the benefit of gonadotropin-releasing hormone agonist in preserving ovarian function and fertility in lymphoma survivors treated with chemotherapy: final long-term report of a prospective randomized trial. J Clin Oncol. 2016;34:2568–2574.
   PubMed Web of Science ®Google Scholar
• Lee WJ, Lee ST, Moon J, et al. Tocilizumab in autoimmune encephalitis refractory to rituximab: an institutional cohort study. Neurotherapeutics. 2016;13:824–832.
   PubMed Web of Science ®Google Scholar
• Quek AM, Britton JW, McKeon A, et al. Autoimmune epilepsy: clinical characteristics and response to immunotherapy. Arch Neurol. 2012;69:582–593.
   PubMed Web of Science ®Google Scholar
• Planaguma J, Haselmann H, Mannara F, et al. Ephrin-B2 prevents N-methyl-D-aspartate receptor antibody effects on memory and neuroplasticity. Ann Neurol. 2016;80:388–400.
   PubMed Web of Science ®Google Scholar